Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 5/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989838 | 1.00 | GPR6 (0.39) | GPR6PIK3C3HCRTR1HCRTR2KDM4C | |
| SCHEMBL30989805 | 0.92 | GPR6 (0.39) | GPR6PIK3C3HCRTR2GPBAR1CCNT1 | |
| SCHEMBL30989950 | 0.91 | GPR6 (0.37) | GPR6PIK3C3HCRTR1HCRTR2KDM4C | |
| SCHEMBL30989774 | 0.91 | GPR6 (0.37) | GPR6PIK3C3HCRTR1HCRTR2KDM4C | |
| SCHEMBL30989824 | 0.89 | GPR6 (0.34) | GPR6HCRTR1HCRTR2KDM4CNTRK1 | |
| SCHEMBL30989905 | 0.81 | KDM4C (0.40) | GPR6PIK3C3KDM4CGPBAR1NTRK1 | |
| SCHEMBL30990026 | 0.81 | MAPK1 (0.41) | GPR6PIK3C3KDM4CGPBAR1 | |
| SCHEMBL30989831 | 0.81 | MAPK1 (0.41) | GPR6PIK3C3KDM4CGPBAR1 | |
| SCHEMBL30989839 | 0.80 | TRPM8 (0.37) | GPR6HCRTR1HCRTR2KDM4C | |
| SCHEMBL30989860 | 0.79 | NTRK1 (0.39) | GPR6NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | claimed |
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |